Option Greeks measure how Prothena Corporation plc (PRTA) option prices respond to changes in the stock price (delta and gamma), the passage of time (theta), implied volatility (vega), and interest rates (rho). These charts plot each Greek by strike, so you can see where an expiration's price risk, time decay, and volatility exposure are concentrated. PRTA implied volatility is in the upper part of its one-year range, which spreads delta and gamma over a wider range of strikes than usual.
Upgrade to view higher order greeks (Vanna, Charm, and Vomma) and multiple expiration dates.
PRTA Option Greeks FAQ
What are option Greeks?
Option Greeks measure how an option's price responds to changes in the stock price (delta and gamma), time (theta), implied volatility (vega), and interest rates (rho).
How do I read the PRTA Greeks charts?
Gamma, theta, and vega are largest for strikes near the Prothena stock price and shrink for strikes far above or below it. Theta grows as expiration gets closer, while vega is larger for expirations further out. Call delta runs from 0 to 1 and put delta from -1 to 0, near 0.50 and -0.50 at the money, and roughly estimates the chance that an option finishes in the money.
How does implied volatility affect PRTA's Greeks?
Prothena IV rank is 72, so implied volatility is in the upper part of its one-year range. Higher implied volatility raises option premiums and daily time decay (theta), and spreads delta and gamma across a wider range of strikes. Over the past year, 30-day implied volatility ranged from 42.7% to 282.4%. See the PRTA implied volatility history for a longer view.
How much gamma and delta do PRTA options carry in total?
Across all open Prothena options on Nov 4, 2026, net gamma exposure was $57.97K and net delta exposure was $1.67M per 1% move in the stock. The PRTA gamma exposure chart shows where that gamma sits by strike.
What is Prothena Corporation plc?
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases.